Emerging targets in pancreatic cancer: Epithelial-mesenchymal transition and cancer stem cells

Jason A. Castellanos, Nipun Merchant, Nagaraj Nagathihalli

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma is one of the most aggressive solid malignancies and is characterized by poor response to current therapy and a dismal survival rate. Recent insights regarding the role of cancer stem cells (CSCs) and epithelial-mesenchymal transition (EMT) in tumorigenesis have brought further understanding to the field and have highlighted new therapeutic targets. CSCs are a distinct subset of cancer cells, with the ability to differentiate into other cell types and self-renew in order to fuel the maintenance of tumor amplification. Transition of a cancer cell from an EMT leads to increased migratory and invasive properties, and thus facilitates initiation of metastasis. EMT is regulated by a complex network of factors that includes cytokines, growth factors, aberrant signaling pathways, transcription factors, and the tumor microenvironment. There is emerging evidence that the EMT process may give rise to CSCs, or at least cells with stem cell-like properties. We review the key pathways involved in both of these processes, the biomarkers used to identify CSCs, and new therapeutic approaches targeting CSCs and EMT in pancreatic ductal adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)1261-1267
Number of pages7
JournalOncoTargets and Therapy
Volume6
DOIs
StatePublished - Sep 12 2013
Externally publishedYes

Fingerprint

Epithelial-Mesenchymal Transition
Neoplastic Stem Cells
Mesenchymal Stromal Cells
Pancreatic Neoplasms
Neoplasms
Adenocarcinoma
Tumor Microenvironment
Intercellular Signaling Peptides and Proteins
Carcinogenesis
Transcription Factors
Stem Cells
Therapeutics
Biomarkers
Maintenance
Cytokines
Neoplasm Metastasis

Keywords

  • Cancer stem cells
  • Epithelial-mesenchymal transition
  • Pancreatic ductal adenocarcinoma
  • Tumor microenvironment

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

Emerging targets in pancreatic cancer : Epithelial-mesenchymal transition and cancer stem cells. / Castellanos, Jason A.; Merchant, Nipun; Nagathihalli, Nagaraj.

In: OncoTargets and Therapy, Vol. 6, 12.09.2013, p. 1261-1267.

Research output: Contribution to journalArticle

@article{fffdd8ad3eee4c13ab999cca36fbee27,
title = "Emerging targets in pancreatic cancer: Epithelial-mesenchymal transition and cancer stem cells",
abstract = "Pancreatic ductal adenocarcinoma is one of the most aggressive solid malignancies and is characterized by poor response to current therapy and a dismal survival rate. Recent insights regarding the role of cancer stem cells (CSCs) and epithelial-mesenchymal transition (EMT) in tumorigenesis have brought further understanding to the field and have highlighted new therapeutic targets. CSCs are a distinct subset of cancer cells, with the ability to differentiate into other cell types and self-renew in order to fuel the maintenance of tumor amplification. Transition of a cancer cell from an EMT leads to increased migratory and invasive properties, and thus facilitates initiation of metastasis. EMT is regulated by a complex network of factors that includes cytokines, growth factors, aberrant signaling pathways, transcription factors, and the tumor microenvironment. There is emerging evidence that the EMT process may give rise to CSCs, or at least cells with stem cell-like properties. We review the key pathways involved in both of these processes, the biomarkers used to identify CSCs, and new therapeutic approaches targeting CSCs and EMT in pancreatic ductal adenocarcinoma.",
keywords = "Cancer stem cells, Epithelial-mesenchymal transition, Pancreatic ductal adenocarcinoma, Tumor microenvironment",
author = "Castellanos, {Jason A.} and Nipun Merchant and Nagaraj Nagathihalli",
year = "2013",
month = "9",
day = "12",
doi = "10.2147/OTT.S34670",
language = "English (US)",
volume = "6",
pages = "1261--1267",
journal = "OncoTargets and Therapy",
issn = "1178-6930",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Emerging targets in pancreatic cancer

T2 - Epithelial-mesenchymal transition and cancer stem cells

AU - Castellanos, Jason A.

AU - Merchant, Nipun

AU - Nagathihalli, Nagaraj

PY - 2013/9/12

Y1 - 2013/9/12

N2 - Pancreatic ductal adenocarcinoma is one of the most aggressive solid malignancies and is characterized by poor response to current therapy and a dismal survival rate. Recent insights regarding the role of cancer stem cells (CSCs) and epithelial-mesenchymal transition (EMT) in tumorigenesis have brought further understanding to the field and have highlighted new therapeutic targets. CSCs are a distinct subset of cancer cells, with the ability to differentiate into other cell types and self-renew in order to fuel the maintenance of tumor amplification. Transition of a cancer cell from an EMT leads to increased migratory and invasive properties, and thus facilitates initiation of metastasis. EMT is regulated by a complex network of factors that includes cytokines, growth factors, aberrant signaling pathways, transcription factors, and the tumor microenvironment. There is emerging evidence that the EMT process may give rise to CSCs, or at least cells with stem cell-like properties. We review the key pathways involved in both of these processes, the biomarkers used to identify CSCs, and new therapeutic approaches targeting CSCs and EMT in pancreatic ductal adenocarcinoma.

AB - Pancreatic ductal adenocarcinoma is one of the most aggressive solid malignancies and is characterized by poor response to current therapy and a dismal survival rate. Recent insights regarding the role of cancer stem cells (CSCs) and epithelial-mesenchymal transition (EMT) in tumorigenesis have brought further understanding to the field and have highlighted new therapeutic targets. CSCs are a distinct subset of cancer cells, with the ability to differentiate into other cell types and self-renew in order to fuel the maintenance of tumor amplification. Transition of a cancer cell from an EMT leads to increased migratory and invasive properties, and thus facilitates initiation of metastasis. EMT is regulated by a complex network of factors that includes cytokines, growth factors, aberrant signaling pathways, transcription factors, and the tumor microenvironment. There is emerging evidence that the EMT process may give rise to CSCs, or at least cells with stem cell-like properties. We review the key pathways involved in both of these processes, the biomarkers used to identify CSCs, and new therapeutic approaches targeting CSCs and EMT in pancreatic ductal adenocarcinoma.

KW - Cancer stem cells

KW - Epithelial-mesenchymal transition

KW - Pancreatic ductal adenocarcinoma

KW - Tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=84884259884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884259884&partnerID=8YFLogxK

U2 - 10.2147/OTT.S34670

DO - 10.2147/OTT.S34670

M3 - Article

AN - SCOPUS:84884259884

VL - 6

SP - 1261

EP - 1267

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

SN - 1178-6930

ER -